Mood Disorders

Safety and Efficacy of Zuranolone in Young Adults With Major Depressive Disorder: A Subgroup Analysis of the Open-Label, Long-Term, Phase 3 SHORELINE Study

Abstract: Introduction There is a greater prevalence of major depressive disorder (MDD) in young adults compared with older adults. Zuranolone is a neuroactive steroid and positive allost...

Zehra Gundogan ;

Ryan Brown , MD;

01/19/2023

Efficacy of Cariprazine as Adjunctive Treatment of Major Depressive Disorder in Patients with Anxiety at Baseline: A Post Hoc Analysis of a Randomized Controlled Trial

Abstract: Background: The efficacy of adjunctive cariprazine treatment on depressive symptoms was evaluated in patients with major depressive disorder (MDD) and inadequate response to ant...

Majid Kerolous , PharmD, MPH;

Leslie Citrome , MD;

01/19/2023

Full Range of Clinical Improvement in Depression Symptoms With Adjunctive Cariprazine Treatment in Patients With Major Depressive Disorder: Results From a Randomized Phase 3 Clinical Trial

Abstract: Background: Clinical trial results often report mean changes, though individual responses may be more valuable in clinical practice. This analysis explored the ability of adjunc...

Majid Kerolous , PharmD, MPH;

Leslie Citrome , MD;

01/19/2023

Safety and Tolerability of Cariprazine for the Adjunctive Treatment of Major Depressive Disorder: A Pooled Analysis of Phase 2B and 3 Clinical Trials

Abstract: Background: Safety of cariprazine in patients with major depressive disorder (MDD) with inadequate response to antidepressants was evaluated. Methods: Safety, tolerability, and ...

Claudia Berger ;

Marco Viscomi ;

01/19/2023

Changes in QIDS-SR16 scores during the COVID-19 pandemic by age group

Abstract: Introduction: The Coronavirus-19 (COVID-19) pandemic represented an unprecedented challenge to the mental health of the global population. The purpose of this study was to deter...

Sarah Cheema ;

01/19/2023

Abstract: Introduction: Major depressive disorder (MDD) is associated with humanistic and economic burden. Little is known about this burden among those with treatment failure. This analy...

Leslie Citrome , MD;

Mousam Parikh ;

01/19/2023

Assessing Treatment Patterns and Economic Impact of Atypical Antipsychotics as the First Adjunctive Treatment for MDD

Abstract: Introduction: Patients with major depressive disorder (MDD) often cycle through multiple treatments prior to receiving an adjunctive atypical antipsychotic (AA). This study eval...

Leslie Citrome , MD;

Mousam Parikh ;

01/19/2023

Full-Spectrum Efficacy of Cariprazine on Manic and Depressive Poles of Bipolar I Disorder in Patients Experiencing Manic or Depressive Episodes: Post Hoc Analysis of Randomized Controlled Trial Data

Abstract: Background: Treating patients with bipolar I disorder (BP-I) with an agent that is only effective against one pole may elicit treatment-emergent affective switch (TEAS), or wors...

Leslie Citrome , MD;

Huy-Binh Nguyen ;

01/19/2023

Effects of Cariprazine on Reducing Symptoms of Hostility and Agitation in Patients with Manic or Mixed Episodes of Bipolar I Disorder

Abstract: Background: Bipolar mania and mixed episodes can be associated with hostility and agitated behavior. Effects of cariprazine on these symptoms were evaluated in this post hoc ana...

Huy-Binh Nguyen ;

Claudia Berger ;

01/19/2023

Early Improvement With Cariprazine as a Predictor of Antidepressant and Anxiolytic Response in Bipolar Depression: Pooled Post Hoc Analysis of 2 Randomized Cariprazine Trials

Abstract: Introduction: Treatment non-response may indicate need for further clinical management; thus, early prediction of treatment response can aid clinical decision-making, including ...

Leslie Citrome , MD;

Huy-Binh Nguyen ;

01/19/2023